To access all features of this site, you must enable Javascript. Here are the instructions for enabling Javascript in your web browser.
From research to industry
The French Alternative Energies and Atomic Energy Commission (CEA) is a key player in research, development and innovation.
Discover the main research areas on which the CEA works.
Find the latest scientific and institutional news of the CEA.
The CEA publishes various scientific and technical periodicals and videos. Through them, you can discover the CEA’s major research topics and the latest technological innovations produced by its laboratories.
Find all the news from CEA's European projects on bioeconomy and health.
HEALTH ＆ LIFE SCIENCES | DIAGNOSIS AND INNOVATIVE TREATMENT | PHARMACOLOGY | DISEASES
Increasing numbers of medicines are molecules that are of biological origin. Unfortunately, such medicines can induce an undesirable response from the immune system. How can we measure such a response? What mechanisms are governing it? Answers to such questions have been provided by the ambitious European Project Abirisk, supported by the Innovative Medicines Initiative
HEALTH ＆ LIFE SCIENCES | DIAGNOSIS AND INNOVATIVE TREATMENT | BIOTECHNOLOGY | DISEASES | AUTOIMMUNE DISEASES | GENETIC DISEASES
The European project NEW DEAL, coordinated by the CEA, aims to develop a highly selective and local therapy based on siRNA and using nanostructures carriers with an improved efficacy and safety profile for all inflammatory bowel diseases (IBD) patients. It could improve efficacity and safety for all inflammatory bowel diseases (IBD) patients.
HEALTH ＆ LIFE SCIENCES | DIAGNOSIS AND INNOVATIVE TREATMENT | GENE AND CELL THERAPY | CELLULAR MECHANISMS | GENETIC DISEASES
The H2020 Biocapan project, coordinated by the CEA, is developing an innovative cell therapy to supplement a poorly functioning pancreas in patients with type 1 diabetes. The two major goals of this therapy - which involves the use of a revolutionary biocapsule - are to prevent transplanted cells from being rejected and to enable them to perform their function. This will enhance patients’ lives, in particular by eliminating the need for immunosuppressive treatments, which often have severe side-effects.
HEALTH ＆ LIFE SCIENCES | NANOMEDICINE | DIAGNOSIS AND INNOVATIVE TREATMENT | CHARACTERISATION | TOOLS ＆ RESEARCH INSTRUMENTS
The European project EUNCL is dedicated to perform and standardize pre-clinical characterization of nanomaterials for medical applications funded under Horizon 2020 Framework Programme. EUNCL also serves as a European knowledge base for researchers and industry ensuring that this knowledge is documented in Europe for the benefit of the European economy, healthcare systems and patients.
HEALTH ＆ LIFE SCIENCES | DIAGNOSIS AND INNOVATIVE TREATMENT | PHARMACOLOGY | STRUCTURAL BIOLOGY | HIGH-THROUGHPUT SCREENING
Based on the study of two hundred poisonous animals, the European project VENOMICS managed to reproduce a bank of 3,616 “natural” toxins compatible with high throughput screening. VENOMICS demonstrated that animal toxins are hundred times more effective in identifying drug candidates than the usual banks of artificial molecules.
HEALTH ＆ LIFE SCIENCES | BIOTECHNOLOGY | DIAGNOSIS AND INNOVATIVE TREATMENT | PHARMACOLOGY | BIOMARKERS | MOLECULAR MECHANISMS | CHEMISTRY
ISOTOPICS is a European research project which aims at the development of new methods for the chemical labeling of drug candidates to streamline drug innovation and to decrease drug attrition.
Top page
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.